Cargando…
A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated death in the United States and has a 5-year survival rate of <4%. Although much effort has been invested in the research and development of pancreatic cancer drugs over the past 30 years, due to the lack of e...
Autores principales: | Jin, Yangbing, Zhang, Zehui, Zou, Siyi, Li, Fanlu, Chen, Hao, Peng, Chenghong, Deng, Xiaxing, Wen, Chenlei, Shen, Baiyong, Zhan, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010262/ https://www.ncbi.nlm.nih.gov/pubmed/33816276 http://dx.doi.org/10.3389/fonc.2021.634881 |
Ejemplares similares
-
Targeting KRAS(G12V) mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
por: Ai, Qi, et al.
Publicado: (2023) -
Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort
por: Zhan, Qian, et al.
Publicado: (2021) -
Preoperative plasma D-dimer independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing radical resection
por: Chen, Haoda, et al.
Publicado: (2021) -
Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study
por: Zou, Siyi, et al.
Publicado: (2022) -
Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study
por: Wen, Chenlei, et al.
Publicado: (2023)